Wepox 4000 IU Injection contains Erythropoietin Alfa, a man-made form of a natural hormone produced by the kidneys. Erythropoietin stimulates the bone marrow to produce more red blood cells and is mainly used to treat anemia — particularly anemia caused by chronic kidney disease (CKD), cancer chemotherapy, or HIV treatment with zidovudine.
Anemia leads to fatigue, weakness, and shortness of breath due to low hemoglobin levels. Wepox helps boost hemoglobin, improve oxygen-carrying capacity, and enhance quality of life in affected patients.
✅ Anemia in Chronic Kidney Disease (CKD) — including dialysis and non-dialysis patients
✅ Anemia due to Chemotherapy — in cancer patients receiving cytotoxic drugs
✅ Anemia from HIV Therapy — particularly with zidovudine use
✅ Reducing Blood Transfusions — in selected pre-surgical patients
Stimulates red blood cell production, improving hemoglobin levels
Reduces the need for blood transfusions in anemia management
Improves energy levels, exercise tolerance, and overall well-being
Used under medical supervision for precise dose titration
Backed by global clinical guidelines in anemia management
Erythropoietin alfa acts by stimulating erythroid progenitor cells in the bone marrow, promoting their development into mature red blood cells. This leads to a gradual rise in hemoglobin and hematocrit levels, correcting anemia over time.
It’s usually given as a subcutaneous (under the skin) or intravenous (IV) injection, with dosing carefully adjusted based on hemoglobin response and patient condition.
Wepox 4000 IU Injection contains Erythropoietin Alfa, a man-made form of a natural hormone produced by the kidneys. Erythropoietin stimulates the bone marrow to produce more red blood cells and is mainly used to treat anemia — particularly anemia caused by chronic kidney disease (CKD), cancer chemotherapy, or HIV treatment with zidovudine.
Anemia leads to fatigue, weakness, and shortness of breath due to low hemoglobin levels. Wepox helps boost hemoglobin, improve oxygen-carrying capacity, and enhance quality of life in affected patients.
✅ Anemia in Chronic Kidney Disease (CKD) — including dialysis and non-dialysis patients
✅ Anemia due to Chemotherapy — in cancer patients receiving cytotoxic drugs
✅ Anemia from HIV Therapy — particularly with zidovudine use
✅ Reducing Blood Transfusions — in selected pre-surgical patients
Stimulates red blood cell production, improving hemoglobin levels
Reduces the need for blood transfusions in anemia management
Improves energy levels, exercise tolerance, and overall well-being
Used under medical supervision for precise dose titration
Backed by global clinical guidelines in anemia management
Erythropoietin alfa acts by stimulating erythroid progenitor cells in the bone marrow, promoting their development into mature red blood cells. This leads to a gradual rise in hemoglobin and hematocrit levels, correcting anemia over time.
It’s usually given as a subcutaneous (under the skin) or intravenous (IV) injection, with dosing carefully adjusted based on hemoglobin response and patient condition.